Hims $HIMS ( ▲ 0.92% ) is making another push into healthcare infrastructure, announcing plans to acquire blood collection company YourBio in a cash deal expected to close in 2026. The company did not disclose the purchase price.
YourBio builds a device that uses bladeless microneedles thinner than an eyelash to collect blood samples without pain. The timing is not random. Hims launched its Labs app just weeks ago, which analyzes patient bloodwork and recommends personalized treatments, so owning part of the sample collection process fits neatly into that strategy.
Hims has been quietly assembling its own diagnostics stack. It bought at-home testing facility Trybe Labs in February for $5.1 million to support new hormone treatment offerings. Its broader labs product runs through a partnership with Quest Diagnostics $DGX ( ▲ 0.02% ) .
The company says it has $345.8 million in cash and cash equivalents, and it already raised $1 billion in May to fuel investments in AI, international expansion, and M&A. That money helped fund its July acquisition of European telehealth platform Zava for $265.7 million.
If the YourBio deal goes through, Hims will own a larger share of the testing journey from sample collection to treatment recommendations, putting more of its fast-growing business under its own roof.